Skip to main content

Table 3 Costs and probability of adverse events

From: Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis

 

Abi-ADT

Doc-ADT

Cost used in the model

Hypertension

121

20.3%

  

98.7

Hypokalaemia

62

10.4%

  

65.0

Increased ALT

33

5.5%

  

225.7

Hyperglycaemia

27

4.5%

  

115.0

Increased AST

26

4.4%

  

225.7

Bone pain

20

3.4%

  

73.6

Cardiac disorder

22

3.7%

  

1000.0

Anaemia

15

2.5%

5

1.3%

271.7

Back pain

14

2.3%

  

73.6

Spinal-cord compression

12

2.0%

  

1235.0

Fatigue

10

1.7%

16

4.1%

540.4

Allergic reaction

  

8

2.1%

75.0

Diarrhoea

  

4

1.0%

31.4

Stomatitis

  

2

0.5%

74.0

Neuropathy

  

4

1.0%

375.8

Thromboembolism

  

3

0.8%

1794.2

Sudden death

  

1

0.3%

3200.0

Thrombocytopenia

  

1

0.3%

3518.0

Neutropaenia

  

47

12.1%

720.8

Febrile neutropaenia

  

24

6.2%

1787.2

Infection with neutropaenia

  

9

2.3%

14,764.1